Overweight Clinical Trials in Morehead City, North Carolina
9 recruitingMorehead City, North Carolina
Showing 1–9 of 9 trials
Recruiting
Phase 3
Efficacy and Safety of KAI-9531 in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes
ObesityOverweight
Kailera1,800 enrolled33 locationsNCT07284875
Recruiting
Phase 3
Efficacy and Safety of KAI-9531 Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes
Obesity With DiabetesOverweight With Diabetes
Kailera1,700 enrolled37 locationsNCT07284901
Recruiting
Phase 3
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
ObesityOverweightAtherosclerotic Cardiovascular Disease
Amgen12,800 enrolled759 locationsNCT07037433
Recruiting
Phase 3
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes
Obesity or OverweightType 2 Diabetes Mellitus
Hoffmann-La Roche1,600 enrolled36 locationsNCT07351058
Recruiting
Phase 2
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
ObesityOverweight
Eli Lilly and Company1,217 enrolled53 locationsNCT06143956
Recruiting
Phase 3
A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
ObesityOverweight
Eli Lilly and Company125 enrolled50 locationsNCT06672549
Recruiting
Phase 3
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
ObesityOverweight
Eli Lilly and Company1,035 enrolled159 locationsNCT07282600
Recruiting
Phase 3
A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
ObesityOverweight
Eli Lilly and Company900 enrolled178 locationsNCT07392190
Recruiting
Phase 3
A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities
ObesityOverweight
Eli Lilly and Company125 enrolled37 locationsNCT06672939